<DOC>
	<DOCNO>NCT00322517</DOCNO>
	<brief_summary>To determine antitumor efficacy safety SU-014813 dose 100 mg orally daily patient Metastatic Breast Cancer</brief_summary>
	<brief_title>Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically cytologically proven diagnosis metastatic breast adenocarcinoma amenable surgery , radiation , combine modality therapy curative intent . Must receive prior treatment anthracycline taxane either concurrently sequentially adjuvant and/or advance disease treatment setting . Patients may receive many 2 chemotherapy regimen advance disease set . Patients whose tumor Her2positive must receive prior trastuzumab therapy . Prior hormonal therapy immunotherapy adjuvant and/or advanced/metastatic disease setting permit . Prior treatment surgery , radiotherapy , chemoembolization therapy , cryotherapy allow therapy affect area measurable disease . Prior treatment &gt; /= 3 regimen chemotherapy metastatic disease set beyond contain anthracyclines taxanes Uncontrolled brain metastasis , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease . Patients complete surgery radiation therapy exist brain metastasis , document increase size previous 3 month asymptomatic</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>